GlassScriptPhysician profile
Melissa A Hoehler
NPI 1891015533
$4,571.29
in general payments reported to CMS, 2019-2025
25 companies · $2,581 in 2025
The $2,581 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $566 · 2022: $258 · 2023: $335 · 2024: $831 · 2025: $2,581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,935 · Travel and Lodging: $704 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,934.85 |
| Travel and Lodging | $704.07 |
| Education | $108.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,434.46 | 2024-2025 | Synchromedii, Intellis Adaptivestim, Inceptiv |
| Saluda Medical Americas, INC. | $781.70 | 2024-2025 | Evoke |
| Collegium Pharmaceutical, INC. | $613.41 | 2023-2025 | Belbuca, Xtampza |
| Abbvie INC. | $370.24 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $343.37 | 2021-2025 | Relistor |
| Grt US Holding, INC. | $175.45 | 2021-2022 | |
| Nevro Corp. | $131.82 | 2024 | Senza |
| Biohaven Pharmaceuticals, INC. | $131.79 | 2021 | |
| Boston Scientific Corporation | $104.33 | 2024-2025 | Wavewriter Alpha Prime 16 |
| Novo Nordisk INC | $72.50 | 2025 | Wegovy |
| Globus Medical, INC. | $65.95 | 2025 | Senza |
| Valinor Pharma, LLC | $60.34 | 2025 | Movantik |
| Biotronik Nro, INC. | $49.92 | 2025 | Prospera |
| Biohaven Pharmaceutical Holding Company LTD. | $30.13 | 2022 | |
| Ferring Pharmaceuticals INC. | $29.62 | 2025 | Euflexxa |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tersera Therapeutics LLC | $28.57 | 2025 | Prialt |
| Amgen INC. | $22.21 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $19.69 | 2025 | |
| Scilex Pharmaceuticals INC. | $18.68 | 2022 | |
| Hikma Pharmaceuticals USA | $16.81 | 2022 | |
| Lilly USA, LLC | $16.05 | 2025 | Zepbound |
| Radius Health, INC. | $15.74 | 2025 | Tymlos |
| Pfizer INC. | $13.29 | 2021 | |
| Horizon Therapeutics Plc | $12.67 | 2021 | |
| Biodelivery Sciences International, INC. | $12.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Hoehler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.